First, SRRM2 is known to mislocalize to tau aggregates in postmortem samples from AD, CBD, and FTLD patients (14), and the degree of mislocalization corresponds with increased severity of pathological tau deposition in humans and mouse models (17). This evidence concerns the gene SRRM2 and Alzheimer disease.